Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.
about
When ubiquitin meets NF-κB: a trove for anti-cancer drug developmentMutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsCurrent status and perspectives of patient-derived xenograft models in cancer research.Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic targetPevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites.Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapyNedd8 regulates inflammasome-dependent caspase-1 activation.Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic applicationFlavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.The cyclomodulin cycle inhibiting factor (CIF) alters cullin neddylation dynamics.Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.Cullin-RING Ligases as attractive anti-cancer targets.SCF ubiquitin ligase-targeted therapies.Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).Overactivated neddylation pathway as a therapeutic target in lung cancer.Ubiquitin-proteasome system, a new anti-tumor target.MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcomaMolecular dynamics simulation on the low sensitivity of mutants of NEDD-8 activating enzyme for MLN4924 inhibitor as a cancer drug.Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.Cullin E3 Ligase Activity Is Required for Myoblast Differentiation.Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.Prospect of divergent roles for the CUL3 system in vascular endothelial cell function and angiogenesis.Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.Protein neddylation and its alterations in human cancers for targeted therapy.The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML
P2860
Q26827754-D1E45407-6926-48DB-BC26-099004E52A35Q28541763-E21C49F0-02D8-45DE-BAAC-81379672EED4Q33667686-EF33CBC7-2A35-4F03-A918-315FFE9D30C9Q33792598-E125BF81-1AE6-44E1-B76E-8445B3E44B99Q34365897-FC94C964-AAE4-4D26-AB38-3E5C09C5AF73Q34465347-6741BF3F-F5DF-4D38-8CE1-A2F9EEC8672AQ34474077-727B9DCE-585D-43E3-91BC-CC9C85E5FDBCQ34476246-23858CE0-4B76-4F78-BD90-1C8B5D56DF06Q34563129-A367B367-1233-403D-A9E9-6AD22DBF3023Q34846646-94BD2DC1-D469-48DF-A5F9-FD8DDF3485E0Q36062128-682BE587-4B23-4B9B-AC3F-3A2182A2E5DDQ36561595-C29BA848-5009-4EBF-9776-69EDA9362E69Q36873556-A4F84A3D-A08D-4DA1-8641-A7BE8D2299BCQ37252274-31F4EFD8-106F-409D-9A6B-693FC4DB97F5Q38026589-BCD6DEFB-70BB-493C-8727-EF03E2F6998CQ38052131-3B01BB5A-F86F-46DC-AAA0-06C9469AFD06Q38059746-9BD98ADA-6019-47F6-A3FF-5925CF307D0DQ38267996-F08E35A1-010D-4AA2-8863-131F588F0220Q38736706-1004E86E-AD4B-4824-A650-984F9577BBB5Q38992669-34AFC222-4373-455F-8D66-DE32B96D1C0BQ39286178-5B492606-B00D-4DDE-BBFD-F4AF5F22DC75Q40851893-07921C2C-AE05-4DBC-8D2B-DBB26D0F65A5Q41429260-50E4B570-3FD7-4CE7-BB41-3F6104975D98Q42292376-DE374464-B937-45DD-92D1-612BDB2D14B8Q45931257-A35AACA1-2324-4DFF-BFF6-E95A981A2423Q46089793-B683B9C3-62CB-410F-AD20-18B1701E9B45Q47159993-B510283A-8DE5-4B25-A738-47993CA8619CQ47692259-245A76BC-F67D-4B86-A64A-BB7BE39F14A8Q47823549-212F8FD7-3424-4DD0-A5CD-EB2759EFF642Q48243218-241208F0-6273-437D-8AA6-2434A04F7A56Q48538797-3168641C-D078-40BC-B94C-893375DEB8A3Q57821081-B1FA096A-CB2A-4F85-944E-DC65499CAED3
P2860
Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Treatment-emergent mutations i ...... ting enzyme inhibitor MLN4924.
@en
Treatment-emergent mutations i ...... ting enzyme inhibitor MLN4924.
@nl
type
label
Treatment-emergent mutations i ...... ting enzyme inhibitor MLN4924.
@en
Treatment-emergent mutations i ...... ting enzyme inhibitor MLN4924.
@nl
prefLabel
Treatment-emergent mutations i ...... ting enzyme inhibitor MLN4924.
@en
Treatment-emergent mutations i ...... ting enzyme inhibitor MLN4924.
@nl
P2093
P1433
P1476
Treatment-emergent mutations i ...... ting enzyme inhibitor MLN4924.
@en
P2093
Alice A McDonald
Benjamin S Amidon
Erik M Koenig
Huay-Keng Loke
James Brownell
James M Gavin
Jessica Riceberg
Joseph B Bolen
Lawrence R Dick
P304
P356
10.1016/J.CCR.2012.02.009
P577
2012-03-01T00:00:00Z